<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400851/" ref="ordinalpos=2675&amp;ncbi_uid=4133354&amp;link_uid=PMC3400851" image-link="/pmc/articles/PMC3400851/figure/F1/" class="imagepopup">Figure 1.  From: Significance of regenerating islet-derived type IV gene expression in gastroenterological cancers. </a></div><br /><div class="p4l_captionBody">Schematic representation of the regenerating islet-derived type IV signaling pathway. Regenerating islet-derived type IV (RegIV) contributes to cell proliferation, inhibition of apoptosis, and carcinogenesis via protein kinase B (Akt) signaling pathway by transactivating the epidermal growth factor receptor (EGFR). The primary signaling pathway is now being investigated. MBS: Mannan-binding sites; PI3K: Phosphoinositide 3-kinase; PIP2: Phosphatidylinositol 4,5-bisphosphate; PIP3: Phosphatidylinositol 4,5-triphosphate; PDK1: Phosphoinositide-dependent kinase-1; Bcl-2: B-cell lymphoma 2.</div></div>